Visioning III: Five-year follow-up for MRI-based prostate cancer screening
Official title: Evaluation of an MRI-based Prostate Cancer Screening Program (VISIONING): 5-Year Follow-up Round (VISIONING III)
Run by University Hospital, Basel, Switzerland · NCT07762911 · Data updated 2026-11-12
This study tests a repeat MRI-based screening approach for men who previously had no cancer signs, to see if a negative bpMRI reliably predicts no significant cancer for at least five years.
Quick facts
| Study type | Interventional |
|---|---|
| Ages | 50 Years and up |
| Sex | Men only |
| Enrollment | 300 (estimated) |
| Sponsor | University Hospital, Basel, Switzerland Academic / other |
| Locations | 1 site (Basel, Canton of Basel-City) |
| Status | Recruiting |
| Started | June 1, 2026 |
| Main results expected | June 1, 2028 |
| Study ends | June 1, 2028 |
| Registry record updated | August 13, 2026 |
| Trial ID | NCT07762911 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Men who previously participated in the VISIONING study, are biopsy-naïve, have a life expectancy over 10 years, and wish to undergo prostate cancer screening.
✕Probably not a fit
Men with large prostate volume, active urinary infections, high symptom scores, or limited life expectancy may derive less benefit from this screening approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
VISIONING III is a prospective, single-center, observational follow-up of men who participated in earlier visioning screening phases. It evaluates the long-term diagnostic performance and safety of a biparametric MRI–based screening pathway, with no new interventions introduced beyond standard diagnostic procedures. The study focuses on five-year incidence of clinically significant prostate cancer (ISUP grade group ≥2) among those with prior negative bpMRI, negative biopsy, or active surveillance for low-risk disease. Primary hypothesis: a negative bpMRI result provides durable protection against csPCa over at least five years, reflected by a high negative predictive value. The study also explores whether re-evaluation after five years identifies a meaningful proportion of previously undetected csPCa according to predefined biopsy criteria.
Why it matters
Potential benefit: Participants could avoid unnecessary biopsies and gain clearer long-term risk insight from repeated bpMRI screening.
How similar studies have gone: Prior VISIONING phases have explored bpMRI-based screening; VISIONING III builds on those findings with long-term follow-up.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * "well-informed men" with the wish for prostate cancer screening: * prostate biopsy naïve * life expectancy \> 10 years * Paticipant in the VISIONING study Exclusion Criteria: * prostate volume \> 80ml * acute urinary tract infection UTI * NIH-CPSI score over or equal to19 * IPSS score over or equal to 20 (leads to initiation of urologic diagnostics and treatment) * life expectancy \< 10 years
Where it's running
-
University Hospital Basel, Urology
Basel, Canton of Basel-City, Switzerland Recruiting
Study contacts
- Study coordinator: Cyrill Rentsch, Prof.
- Email: cyrill.rentsch@usb.ch
- Phone: +41 61 32 87122
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Targeted alpha therapy for B7-H3 expressing solid tumors using AKY-2519
This phase 1b trial tests a radiolabeled drug (AKY-2519) to see if it's safe and tolerable in adults with B7-H3 positive advanced solid tumors, including NSCLC and SCLC, with imaging to help guide use.
-
PSMA-guided surgery and tissue-resident T cells in node-positive prostate cancer
This study tests whether PSMA-guided surgery can help identify and study tissue-resident T cells in prostate cancer that has spread to lymph nodes.
-
Predictive factors for response to Lu-177 PSMA therapy in metastatic castration-resistant prostate cancer
This study tests whether imaging, dose measurements, and blood tests can predict which men with metastatic castration-resistant prostate cancer will respond to Lu-177 PSMA therapy.
-
Salvage high-dose-rate brachytherapy for locally recurrent prostate cancer
This observational study tests whether salvage HDR brachytherapy can help men with locally recurrent prostate cancer after initial radiotherapy, using advanced imaging and biopsy to guide treatment.
-
Multi-peptide Vaccination and PSMAxCD3 Antibody Therapy for Prostate Cancer with Biochemical Recurrence
This phase 2 trial tests whether a PSMA-targeted bispecific antibody (CC-1), a prostate cancer peptide vaccine (VAC-XS15-PC01), or both can be given safely and help control biochemical recurrence after local therapy in men with prostate cancer.
-
Lutetium-177 Ludotadipep for advanced prostate cancer
This study tests whether adding Lu-177 Ludotadipep to standard care helps men with metastatic castration-resistant prostate cancer live longer without their disease getting worse.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.